ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

RYTARY
Parkinsonism
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

RYTARY Rx

Generic Name and Formulations:
Carbidopa, levodopa; 23.75mg/95mg, 36.25mg/145mg, 48.75mg/195mg, 61.25mg/245mg; ext-rel caps.

Company:
Impax Laboratories, Inc.

Therapeutic Use:

Indications for RYTARY:

Treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Adult:

Swallow whole. If difficulty swallowing, may open capsule and sprinkle contents on applesauce (1–2tbsp); consume immediately. Individualize. Levodopa-naive: initially 23.75mg/95mg 3 times daily for the first 3 days; may increase to 36.25mg/145mg 3 times daily on the fourth day; up to max 97.5mg/390mg 3 times daily. May increase to max 5 times daily if more frequent dosing needed and tolerated. Max daily dose: 612.5mg/2450mg. Converting from IR carbidopa-levodopa: see full labeling. Currently taking carbidopa-levodopa with concomitant COMT inhibitors (eg, entacapone): may need to increase initial daily dose; see full labeling.

Children:

Not established.

Contraindications:

During or within 2 weeks of nonselective MAOIs (eg, phenelzine, tranylcypromine).

Warnings/Precautions:

Not interchangeable with other carbidopa-levodopa products. Sleep disorders: consider discontinuing if significant daytime sleepiness occurs. History of MI or arrhythmias; monitor cardiac function. Increased risk of hallucinations and psychosis. Major psychotic disorder: not recommended. Impulse control disorders: consider reducing dose or discontinuing if occurs. Peptic ulcer. Glaucoma: monitor intraocular pressure. Perform skin exams to monitor for melanoma. Withdrawal-emergent hyperpyrexia or confusion: avoid sudden discontinuation or rapid dose reduction. Pregnancy (Cat.C). Nursing mothers.

Interactions:

See Contraindications. Orthostatic hypotension with MAO-B inhibitors (eg, rasagiline, selegiline); monitor. Antagonized by dopamine D2 receptor antagonists (eg, phenothiazines, butyrophenones, risperidone, metoclopramide), isoniazid, iron salts. Delayed absorption with high-fat, high-calorie meals.

Pharmacological Class:

Dopa-decarboxylase inhibitor + dopamine precursor.

Adverse Reactions:

Nausea, dizziness, headache, insomnia, abnormal dreams, dry mouth, dyskinesia (reduce doses), anxiety, constipation, vomiting, orthostatic hypotension.

How Supplied:

Ext-rel caps—100, 240

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs